Skip to main content

Table 3 Base case results

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

  Non-prophylaxis Palivizumab Incremental palivizumab vs non-prophylaxis.
QALYs 5.19 5.26 0.0731
COSTS
Total costs €671.68 €2,110.71 €1,439.03
 Prophylaxis costs (pharmaceutical and administration) €0.00 €1,886.78 €1,886.78
 Hospital related costs €246.44 €78.14 €-168.30
 Recurrent wheezing management costs €425.23 €145.78 €-279.45
ICUR (€/QALY gained with palivizumab vs non-prophylaxis 1,9697.69
  1. ICUR: incremental cost utility ratio; QALY: quality adjusted life years